慢性肾脏病临床试验结局:跨国德尔菲调查
该研究通过两轮国际德尔菲调查,纳入来自73个国家的1399名慢性肾脏病患者、照护者和健康专业人员,评估临床试验结局的重要性。结果显示,患者和照护者最重视的结局包括肾功能、透析或移植需求、生活参与、心血管疾病和死亡。患者/照护者对多数结局的评分高于健康专业人员,而健康专业人员更关注死亡、住院和心血管疾病。
要点
- 肾功能、透析/移植需求、生活参与、心血管疾病和死亡是 CKD 试验最优先结局。
- 患者/照护者对22个结局中的17个评分高于健康专业人员。
- 健康专业人员更重视死亡、住院和心血管疾病。
核心结论
- 在 CKD 临床试验中,患者、照护者和健康专业人员共同优先关注的结局为肾功能、透析/移植需求、生活参与、心血管疾病和死亡。
研究设计与样本
- 研究为在线两轮国际德尔菲调查。
- 第一轮有来自73个国家的1399名参与者完成,包括628名(45%)患者/照护者和771名(55%)健康专业人员。
- 第二轮有来自63个国家的790名参与者完成,应答率56%,包括383名(48%)患者/照护者和407名(52%)健康专业人员。
主要发现
- 总体排名前五的结局为肾功能、透析/移植需求、生活参与、心血管疾病和死亡。
- 在最终轮,患者/照护者对22个结局中的17个给出了更高的评分。
- 健康专业人员对死亡、住院和心血管疾病给予更高优先级(平均差异>0.3)。
- 共识标准为两组中位评分≥7、平均评分>7,且两组评为「极其重要」的比例均>50%。
关键数值与推荐
- 重要性评分采用 Likert 量表(7-9 表示极其重要)和最佳-最差量表。
- 共识定义为两组中位评分≥7、平均评分>7,且两组评为「极其重要」的比例均>50%。
临床怎么用
- 肾内科智能体在解读 CKD 临床试验时,应优先关注肾功能、透析/移植需求、生活参与、心血管疾病和死亡等核心结局。
- 与患者沟通时应重视其高度优先的结局,如生活参与,并平衡健康专业人员关注的死亡、住院和心血管疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many outcomes of high priority to patients and clinicians are infrequently and inconsistently reported across trials in chronic kidney disease (CKD), which generates research waste and limits evidence-informed decision making. We aimed to generate consensus among patients/caregivers and health professionals on critically important outcomes for trials in CKD prior to kidney failure and the need for kidney replacement therapy, and to describe the reasons for their choices. METHODS: This was an online two-round international Delphi survey. Adult patients with CKD (all stages and diagnoses), caregivers and health professionals who could read English, Spanish or French were eligible. Participants rated the importance of outcomes using a Likert scale (7-9 indicating critical importance) and a Best-Worst Scale. The scores for the two groups were assessed to determine absolute and relative importance. Comments were analysed thematically. RESULTS: In total, 1399 participants from 73 countries completed Round 1 of the Delphi survey, including 628 (45%) patients/caregivers and 771 (55%) health professionals. In Round 2, 790 participants (56% response rate) from 63 countries completed the survey including 383 (48%) patients/caregivers and 407 (52%) health professionals. The overall top five outcomes were: kidney function, need for dialysis/transplant, life participation, cardiovascular disease and death. In the final round, patients/caregivers indicated higher scores for most outcomes (17/22 outcomes), and health professionals gave higher priority to mortality, hospitalization and cardiovascular disease (mean difference >0.3). Consensus was based upon the two groups yielding median scores of ≥7 and mean scores >7, and the proportions of both groups rating the outcome as 'critically important' being >50%. Four themes reflected the reasons for their priorities: imminent threat of a health catastrophe, signifying diminishing capacities, ability to self-manage and cope, and tangible and direct consequences. CONCLUSION: Across trials in CKD, the outcomes of highest priority to patients, caregivers and health professionals were kidney function, need for dialysis/transplant, life participation, cardiovascular disease and death.
引用
- Matus Gonzalez A, Evangelidis N, Howell M, et al. Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals. Nephrol Dial Transplant. 2024. PMID: 38236705. doi:10.1093/ndt/gfae010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。